Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension.
OBJECTIVE
To investigate the impacts of Xuezhikang (XZK) or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells (CEPCs) in essential hypertensive (EH) patients.


METHODS
Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group (ATH group, 29 cases), the pravastatin treatment group (PRA group, 29 cases) and the Xuezhikang treatment group (XZK group, 30 cases). Patients in the 3 groups were treated with routine antihypertensive drugs. In addition, pravastatin and Xuezhikang were given to the patients in the PRA group and XZK group, respectively. After an eight-week treatment, CEPCs were counted using a laser scanning confocal microscope, and their proliferation function was evaluated by the MTT colorimetric assay and the adherent cell number was counted to estimate the adhesion function.


RESULTS
After the treatment, CEPCs in the PRA group (116.60+/-5.70) and XZK group (114.40+/-6.55) was significantly higher than that in the ATH group (88.00+/-6.32, P<0.01). CEPCs proliferation capability and the adhesion function in the PRA group (0.406+/-0.016, 33.60+/-4.26) and XZK group (0.415+/-0.018, 34.30+/-3.77) were obviously superior to those in the ATH group (0.333+/-0.021, P<0.01; 23.30+/-3.19, P<0.01). No significant difference was found between the pravastatin group and the XZK group.


CONCLUSIONS
Combined use of XZK or pravastatin with the anti-hypertensive therapy could increase the CEPCs number and improve their function in EH patients with the blood pressure controlled by antihypertensive drugs, leading to benefits independent of pressure-lowering effects.
Lu
Li
L
The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zhou
Jian-zhong
JZ
Wang
Li
L
Zhang
Tie-xu
TX
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D050034:Antidiuretic Agents / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001772:Blood Cell Count; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D042783:Endothelial Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D055048:Integrative Medicine / Q000379:methods; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage*; D013234:Stem Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology
D000924:Anticholesteremic Agents; D050034:Antidiuretic Agents; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004365:Drugs, Chinese Herbal; C496822:xuezhikang; D017035:Pravastatin
Science. 1997 Feb 14;275(5302):964-7
9020076
Hypertens Res. 2003 Sep;26(9):699-704
14620924
N Engl J Med. 2005 Sep 8;353(10):999-1007
16148285
Circulation. 2003 Sep 23;108(12):1520-6
12952850
Circulation. 2004 Aug 24;110(8):915-20
15313947
Circulation. 2005 Jun 7;111(22):2981-7
15927972
J Hypertens. 2005 Oct;23(10):1831-7
16148606
Circulation. 2001 Jun 19;103(24):2885-90
11413075
J Clin Invest. 2001 Aug;108(3):391-7
11489932
J Hypertens. 1999 Feb;17(2):151-83
10067786
Basic Res Cardiol. 2004 Jan;99(1):61-8
14685707
Hypertens Res. 2007 Nov;30(11):1119-28
18250561
Circ Res. 2003 May 16;92(9):1049-55
12676819
Circulation. 2002 Dec 17;106(25):3143-421
12485966